Basilea Pharmaceutica Dirección

Dirección controles de criterios 3/4

El CEO de Basilea Pharmaceutica's es David Veitch , nombrado en Apr 2018, tiene una permanencia de 6.08 años. compensación anual total es CHF1.75M, compuesta por 35% salario y 65% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.011% de las acciones de la empresa, por valor de CHF51.35K. La antigüedad media del equipo directivo y de la junta directiva es de 6.3 años y 9.1 años, respectivamente.

Información clave

David Veitch

Chief Executive Officer (CEO)

CHF1.7m

Compensación total

Porcentaje del salario del CEO	35.0%
Permanencia del CEO	6.1yrs
Participación del CEO	0.01%
Permanencia media de la dirección	6.3yrs
Promedio de permanencia en la Junta Directiva	9.1yrs

Actualizaciones recientes de la dirección

Shareholders May Be More Conservative With Basilea Pharmaceutica AG's (VTX:BSLN) CEO Compensation For Now

Apr 18

Recent updates

Shareholders May Be More Conservative With Basilea Pharmaceutica AG's (VTX:BSLN) CEO Compensation For Now

Apr 18

Does Basilea Pharmaceutica (VTX:BSLN) Deserve A Spot On Your Watchlist?

Sep 20

Robust Earnings May Not Tell The Whole Story For Basilea Pharmaceutica (VTX:BSLN)

Feb 17

Revenue Downgrade: Here's What Analysts Forecast For Basilea Pharmaceutica AG (VTX:BSLN)

Jul 01

Analysts Expect Breakeven For Basilea Pharmaceutica AG (VTX:BSLN) Before Long

Mar 24

If You Had Bought Basilea Pharmaceutica's (VTX:BSLN) Shares Three Years Ago You Would Be Down 19%

Feb 18

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de David Veitch en comparación con los beneficios de Basilea Pharmaceutica?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	CHF2m	CHF611k	CHF10m
Sep 30 2023	n/a	n/a	CHF33m
Jun 30 2023	n/a	n/a	CHF56m
Mar 31 2023	n/a	n/a	CHF34m
Dec 31 2022	CHF2m	CHF599k	CHF12m
Sep 30 2022	n/a	n/a	CHF6m
Jun 30 2022	n/a	n/a	CHF851k
Mar 31 2022	n/a	n/a	-CHF3m
Dec 31 2021	CHF2m	CHF594k	-CHF7m
Sep 30 2021	n/a	n/a	-CHF26m
Jun 30 2021	n/a	n/a	-CHF45m
Mar 31 2021	n/a	n/a	-CHF30m
Dec 31 2020	CHF1m	CHF589k	-CHF15m
Sep 30 2020	n/a	n/a	-CHF6m
Jun 30 2020	n/a	n/a	CHF3m
Mar 31 2020	n/a	n/a	-CHF10m
Dec 31 2019	CHF1m	CHF583k	-CHF22m
Sep 30 2019	n/a	n/a	-CHF23m
Jun 30 2019	n/a	n/a	-CHF24m
Mar 31 2019	n/a	n/a	-CHF28m
Dec 31 2018	CHF2m	CHF529k	-CHF31m

Compensación vs. Mercado: La compensación total de David($USD1.91M) está por encima de la media de empresas de tamaño similar en el mercado Swiss ($USD1.17M).

Compensación vs. Ingresos: La compensación de David ha sido consistente con los resultados de la empresa en el último año.

CEO

David Veitch (58 yo)

6.1yrs

Permanencia

CHF1,745,679

Compensación

Mr. David Veitch has been the Chief Executive Officer of Basilea Pharmaceutica Ltd. since April 19, 2018 and Basilea Pharmaceutica International Ltd., since September 1, 2014. Mr. Veitch joined Basilea in...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
David Veitch	Chief Executive Officer	6.1yrs	CHF1.75m	0.011% CHF 56.0k
Adesh Kaul	Chief Financial Officer	5.1yrs	sin datos	0.0041% CHF 21.5k
Gerrit Hauck	Chief Technology Officer	6yrs	sin datos	sin datos
Laurenz Kellenberger	Chief Scientific Officer	15.3yrs	sin datos	0.0041% CHF 21.5k
Marc Engelhardt	Chief Medical Officer	6.3yrs	sin datos	sin datos
Peer Schroder	Head of Corporate Communications & Investor Relations	no data	sin datos	sin datos
Damian Heller	General Counsel & Corporate Secretary	6.8yrs	sin datos	sin datos
Andreas Kumin	Head of Corporate Development	no data	sin datos	sin datos
Ursula Eberhardt	Head of Global Human Resources	7.3yrs	sin datos	sin datos
Mark Jones	Head of Project Management & Preclinical Development	6.3yrs	sin datos	sin datos
Peter Bielmeier	Head of Global Quality Management	1.7yrs	sin datos	sin datos
Mohammed Benghezal	Head of Biology	no data	sin datos	sin datos

6.3yrs

Permanencia media

57yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de BSLN es experimentado (6.3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Nicole Onetto	Independent Non-Executive Director	7.1yrs	CHF192.13k	0.0061% CHF 31.8k
Leonard Kruimer	Independent Non-Executive Director	2.1yrs	CHF186.88k	sin datos
Domenico Scala	Independent Chairman of the Board	12.5yrs	CHF337.68k	0.0049% CHF 25.4k
Alf Gunnar Nicklasson	Independent Non-Executive Director	11.1yrs	CHF211.75k	0.015% CHF 75.7k
Carole Sable	Independent Non-Executive Director	1.1yrs	CHF192.13k	sin datos
Thomas Werner	Independent Vice-Chairman	12.5yrs	CHF224.80k	0.0099% CHF 51.4k

9.1yrs

Permanencia media

66yo

Promedio de edad

Junta con experiencia: La junta directiva de BSLN se considera experimentada (9 años de antigüedad promedio).

Basilea Pharmaceutica Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Shareholders May Be More Conservative With Basilea Pharmaceutica AG's (VTX:BSLN) CEO Compensation For Now

Basilea Pharmaceutica AG, Annual General Meeting, Apr 24, 2024

Basilea Pharmaceutica AG, Annual General Meeting, Apr 26, 2023

High number of new directors

Insufficient new directors

Basilea Pharmaceutica Ltd. Approves Appointment of Leonard Kruimer as New Member of Board and as Chairman of the Audit Committee

Recent updates

Basilea Reports Presentation of New Data for Ceftobiprole (Zevtera®) At Escmid Global 2024

Shareholders May Be More Conservative With Basilea Pharmaceutica AG's (VTX:BSLN) CEO Compensation For Now

Consensus EPS estimates increase by 15%

Price target increased by 7.6% to CHF70.58

Basilea Pharmaceutica AG to Report First Half, 2024 Results on Aug 13, 2024

New minor risk - Negative shareholders equity

Full year 2023 earnings: EPS exceeds analyst expectations

New minor risk - Share price stability

Consensus EPS estimates fall by 78%

Price target decreased by 7.6% to CHF69.90

Consensus EPS estimates fall by 30%

Basilea Pharmaceutica AG to Report Fiscal Year 2023 Results on Feb 13, 2024

Basilea Pharmaceutica AG, Annual General Meeting, Apr 24, 2024

Does Basilea Pharmaceutica (VTX:BSLN) Deserve A Spot On Your Watchlist?

Basilea Pharmaceutica AG Revises Earnings Guidance for the Year 2023

First half 2023 earnings: EPS and revenues exceed analyst expectations

New minor risk - Share price stability

Price target decreased by 9.0% to CHF67.18

Consensus EPS estimates increase by 13%

Robust Earnings May Not Tell The Whole Story For Basilea Pharmaceutica (VTX:BSLN)

Basilea Pharmaceutica AG to Report First Half, 2023 Results on Aug 15, 2023

Basilea Pharmaceutica Ltd Revises Earnings Guidance for the Year 2022

Basilea Pharmaceutica AG, Annual General Meeting, Apr 26, 2023

Basilea Pharmaceutica AG to Report Fiscal Year 2022 Results on Feb 14, 2023

Price target decreased to CHF68.58

Price target decreased to CHF68.58

Basilea Pharmaceutica AG 's ERADICATE Phase 3 Study Results Highlight the Potential Role of Ceftobiprole in the Treatment of Staphylococcus Aureus Bacteremia (Sab)

Consensus estimates of losses per share improve by 13%

Consensus estimates of losses per share improve by 10%

Basilea Pharmaceutica AG Revises Earnings Guidance for the Full Year 2022

Price target increased to CHF73.98

First half 2022 earnings: EPS and revenues exceed analyst expectations

Basilea Pharmaceutica AG Provides Earnings Guidance for the Year 2022

Basilea Pharmaceutica AG Provides Earnings Guidance for the Year 2022

Revenue Downgrade: Here's What Analysts Forecast For Basilea Pharmaceutica AG (VTX:BSLN)

Consensus forecasts updated

Basilea Pharmaceutica Ltd. Positive Results of Phase 3 Eradicate Study with Ceftobiprole in Staphylococcus Aureus Bacteremia

Basilea Pharmaceutica AG Reports Progress on the Implementation of Its Strategy to Focus on Anti-Infectives

Basilea Pharmaceutica AG to Report First Half, 2022 Results on Aug 16, 2022

High number of new directors

Price target decreased to CHF77.00

Insufficient new directors

Basilea Pharmaceutica Ltd. Approves Appointment of Leonard Kruimer as New Member of Board and as Chairman of the Audit Committee

Basilea Pharmaceutica Ltd. Reports Preclinical Data on Oncology Drug Candidates BAL0891

Price target decreased to CHF77.50

Basilea Reports Preclinical Data on Anti-Cancer Activity of Novel Oncology Drug Candidate BAL0891 at ESMO TAT congress

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus forecasts updated

Forecast breakeven date moved forward to 2023

Basilea Pharmaceutica AG Provides Earnings Guidance for the Fiscal Year 2022

Basilea Reports Updated Interim Results for iCCA Patients with FGFR2 Mutations and Amplifications from Phase 2 Study FIDES-01 at ASCO GI Cancers Symposium

Basilea Announces Completion of Patient Enrolment in Phase 3 Eradicate Study Investigating Ceftobiprole in Bloodstream Infections

Forecast to breakeven in 2024

Basilea Pharmaceutica Ltd. Announces FDA Approval of Investigational New Drug Application for Novel Oncology Drug Candidate BAL0891

Basilea Pharmaceutica Ltd. Presents Full Safety and Efficacy Data Set on Derazantinib in Patients with FGFR2 Fusion-Positive iCCA at ESMO Congress

First half 2021 earnings released: CHF1.72 loss per share (vs CHF0.92 profit in 1H 2020)

No longer forecast to breakeven

Basilea Pharmaceutica Ltd. Provides Updates on Efficacy Data with Derazantinib in Bile Duct Cancer and on Ongoing Clinical Programs in Urothelial and Gastric Cancer

Basilea Pharmaceutica AG Wins Carb-X Grant of Up to USD 2.7 Million to Develop Novel-Class Antibiotic

Analysts Expect Breakeven For Basilea Pharmaceutica AG (VTX:BSLN) Before Long

Basilea Pharmaceutica AG has completed a Follow-on Equity Offering in the amount of CHF 45.75 million.

If You Had Bought Basilea Pharmaceutica's (VTX:BSLN) Shares Three Years Ago You Would Be Down 19%

PHT International Inc. entered into an agreement to acquire Basilea Pharmaceutica China Ltd. from Basilea Pharmaceutica AG (SWX:BSLN) for $6.3 million.

Basilea Pharmaceutica Ltd. Reports derazantinib/PD-L1 Checkpoint Inhibitor Combination Results from Dose-Finding Part of FIDES-02 Study in Patients with Solid Tumors at ASCO GU Symposium

Basilea Pharmaceutica Ltd. Promotes Potential First-In-Class Small-Molecule Kinase Inhibitor

New 90-day high: CHF58.60

Analysts update estimates

Basilea Pharmaceutica Ltd. Reports Positive Topline Results from Phase 2 Study FIDES-01 for Derazantinib in FGFR2 Gene Fusion-Positive Patients with Bile Duct Cancer (iCCA)

New 90-day high: CHF55.65